• Co-lead the cross-functional Special Ophthmaology Launch Readiness Team, developing commercial brand plans, business strategies, and tactics with Marketing to ensure the success of marketed and pipeline products.• Co-lead development of integrated evidence-generation plans for pipeline products in partnership with Market Access. • Provide strategic medical and scientific expertise for pipeline products.• Canadian representative on Global Medical Affairs and Clinical Development Teams providing regional input into global clinical development, Medical Affairs and Commercial strategic plans.• Proactively identify and develop Canadian scientific and medical experts to enhance market development and support for Janssen products.• Support the design, implementation, and execution of local medical symposiums and advisory board meetings.• Secure global and local endorsement for local clinical and investigator-initiated trials

• Co-led therapeutic area cross-functional teams developing commercial brand plans, business strategies and tactics with the Marketing to ensure the success of marketed and pipeline products.• Provided strategic medical and scientific expertise for marketed and pipeline products. Using HCP level data, designed a Medical Affairs scientific pre-launch engagement plan for next-generation biologic that resulted in the fastest market uptake in the dermatology marketplace compared to its competitors.• Co-led development of integrated evidence-generation plans for marketed and pipeline products in partnership with Market Access. Published an RSV healthcare utilization study.• Representative on Global Medical Affairs and Clinical Development Teams providing regional input into global clinical development, Medical Affairs and Commercial strategic plans.• Proactively identified and developed Canadian scientific and medical experts to enhance market development and support for Janssen products.• Supported design, implementation, and execution of global and local medical symposiums and advisory board meetings.• Secured global and local endorsement for local clinical and investigator-initiated trials.• Led, developed, and coached the Dermatology MSL Team (2014 - 2020). Responsible for planning, directing, and coordinating the MSLs' activities to achieve clinical and business objectives within the Dermatology therapeutic area. Worked cross-functionally to identify, develop, and implement MSL strategies and tactics and monitor results.• Study responsible scientist for a global psoriasis RWE registry, PSOLAR. Organized and led annual steering committee meetings and secured a Canadian demographic publication.• Secured senior leadership endorsement and funding to initiate and lead a Gen AI initiative to evaluate MSL CRM notes for insight generation and HCP sentiment. The pilot resulted in improved MSL tactical plans and brand strategies.

• Through one-to-one meetings and presentations to provincial immunization committees, provided strategic medical and scientific expertise for respiratory products to external experts and public health decision-makers.• Assisted in developing and implementing commercial and medical tactical plans for launched and pipeline products. • Developed MSL brand-specific territory plans for vaccines and respiratory to ensure the success of marketed and pipeline products.• Provided medical leadership by interpreting and leveraging scientific evidence and proactively addressing potential issues.• Proactively identify and develop Canadian and regional medical and scientific experts to enhance market development and support for GSK products.

I• Medical Business Partner within the Cervarix™ franchise team contributing to the overall product strategy for ideal global market positioning.• Provided global medical advice for Cervarix™ and vaccination in general to franchise teams, GSK regional offices and local operating countries.• Global medical reference contact for GSK local operating countries and regional offices.• GSK medical contact for a network of global External Experts, health officials, policymakers, and clinicians.• Led cross-functional teams to develop long-term strategies for supporting and developing global, regional, and local HPV vaccination and cervical screening guidelines.• Led cross-functional team to develop long-term strategy and process for successful tendering of Cervarix™ and medical lead to develop global medical tender documents.• Led the initiative to develop a global platform for the development and execution of external speakers’ bureaus.• Assisted Vaccine Leadership Team in developing and implementing Cervarix™ life cycle management and next-generation HPV vaccine.

• Through one-to-one meetings and presentations to provincial immunization committees, provided strategic medical and scientific expertise for marketed and pipeline vaccines products to external experts and public health decision-makers.• Assisted in developing and implementing commercial and medical tactical plans for launched and pipeline products. • Developed MSL brand-specific plans for vaccines to ensure the success of marketed and pipeline products.• Provided medical leadership by interpreting and leveraging scientific evidence and proactively addressing potential issues.• Proactively identify and develop Canadian and regional medical and scientific experts to enhance market development and support for GSK products.• Supported the training and roll-out of the H1N1 pandemic flu vaccine, providing field-based training to Atlantic public health workers.

• Provided strategic medical and scientific expertise in various therapeutic fields (vaccines, CNS, psychiatry, arthritis, oncology, gastroenterology, respiratory) for marketed and pipeline products.• Led, developed, and implemented medical tactical plans for marketed and pipeline products.• Developed brand-specific business strategies and tactics with Marketing Teams to ensure the success of marketed and pipeline products. Received global recognition and award for securing GSK's first Synflorix public tender and implementation in the national vaccination program.• Canadian representative on global project and clinical development teams providing LOC input into global clinical development and international commercial strategic plans.• Assisted in optimizing immunization guidelines for Rotarix™, Priorix tetra™ and Synflorix™ vaccines by writing product clinical overviews for the National Advisory Committee on Immunization (NACI).• Presented to provincial and national immunization committees, NACI, Quebec Immunization Committee (CIQ) and Vaccine Supply Working Group (VSWG).• Proactively identified and developed Canadian scientific and medical experts to enhance market development and support for GSK products.• Led the design, implementation and execution of local medical symposiums and advisory board meetings.• Secured global and local endorsement and financial support for the conduct of 7 local clinical trials. Sponsored a pragmatic clinical trial that demonstrated the real-world effectiveness of Rotarix in infants and the herd-immunity benefits in elderly individuals. NACI incorporated the RWE data in their recommendation, endorsing a national rotavirus vaccination program.

• Led a team of statisticians, epidemiologists, and outcomes research experts to support the organization's day-to-day medical affairs regarding GSK products and diseases. • Managed a diverse set of S&E capabilities in a matrix environment that included multiple customer groups and therapy areas. Balance and optimize support across Marketing, Reimbursement, Medical Affairs, and Sales Excellence.• Ensured S&E-led research projects were planned and integrated within the Medical Strategic Operating Plan (MedSOPP), providing maximum value for the local business.• Worked with Stats & Epi staff to cultivate relationships with GSK Global Health Outcomes (GHO) and WW Epidemiology that would benefit the local business.